1. Home
  2. CANF vs BOXL Comparison

CANF vs BOXL Comparison

Compare CANF & BOXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CANF
  • BOXL
  • Stock Information
  • Founded
  • CANF 1994
  • BOXL 1985
  • Country
  • CANF Israel
  • BOXL United States
  • Employees
  • CANF N/A
  • BOXL N/A
  • Industry
  • CANF Biotechnology: Pharmaceutical Preparations
  • BOXL Telecommunications Equipment
  • Sector
  • CANF Health Care
  • BOXL Telecommunications
  • Exchange
  • CANF Nasdaq
  • BOXL Nasdaq
  • Market Cap
  • CANF 9.6M
  • BOXL 10.9M
  • IPO Year
  • CANF N/A
  • BOXL 2017
  • Fundamental
  • Price
  • CANF $0.50
  • BOXL $1.61
  • Analyst Decision
  • CANF Strong Buy
  • BOXL Buy
  • Analyst Count
  • CANF 2
  • BOXL 3
  • Target Price
  • CANF $14.50
  • BOXL $5.00
  • AVG Volume (30 Days)
  • CANF 280.9K
  • BOXL 348.2K
  • Earning Date
  • CANF 11-27-2025
  • BOXL 11-12-2025
  • Dividend Yield
  • CANF N/A
  • BOXL N/A
  • EPS Growth
  • CANF N/A
  • BOXL N/A
  • EPS
  • CANF N/A
  • BOXL N/A
  • Revenue
  • CANF $560,000.00
  • BOXL $113,560,000.00
  • Revenue This Year
  • CANF $461.72
  • BOXL N/A
  • Revenue Next Year
  • CANF N/A
  • BOXL N/A
  • P/E Ratio
  • CANF N/A
  • BOXL N/A
  • Revenue Growth
  • CANF N/A
  • BOXL N/A
  • 52 Week Low
  • CANF $0.47
  • BOXL $1.06
  • 52 Week High
  • CANF $3.02
  • BOXL $10.65
  • Technical
  • Relative Strength Index (RSI)
  • CANF 31.15
  • BOXL 40.01
  • Support Level
  • CANF $0.49
  • BOXL $1.90
  • Resistance Level
  • CANF $0.55
  • BOXL $2.16
  • Average True Range (ATR)
  • CANF 0.03
  • BOXL 0.16
  • MACD
  • CANF -0.00
  • BOXL -0.07
  • Stochastic Oscillator
  • CANF 13.94
  • BOXL 2.83

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions including flat panels, LED video walls, and digital signage. The company also distributes science, technology, engineering, and math (or STEM) products, including 3D printing and robotics solutions and a portable science lab.

Share on Social Networks: